Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…Abstract Number: 2787 • 2017 ACR/ARHP Annual Meeting
Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor approved in the EU for the treatment (trt) of moderately to…Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…Abstract Number: 1089 • 2017 ACR/ARHP Annual Meeting
Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry
Background/Purpose: Tuberculosis (TB) testing prior to biologic DMARD use helps prevent potentially fatal, medication-related adverse events and is a National Quality Forum-endorsed quality measure. We…Abstract Number: 1507 • 2016 ACR/ARHP Annual Meeting
Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Background/Purpose: According to the report by WHO, Japan is still in moderately-prevailing countries of TB. The annual incidence of TB in Japan is approximately 15/100,000,…Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting
Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…Abstract Number: 2142 • 2015 ACR/ARHP Annual Meeting
Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Background/Purpose: Interferon-ƴ release assays (IGRAs) offer the possibility of an improved method to detect TB infections in pts with autoimmune disorders. Compare results of…Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting
Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Background/Purpose: Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…Abstract Number: 1138 • 2013 ACR/ARHP Annual Meeting
Tuberculin Skin Test and Booster Phenomenon In a Rheumatoid Arthritis Population. Differences Between Early and Established Disease
Background/Purpose: Tuberculosis (TB) remains a major global health problem. Chronic inflammation in Rheumatoid Arthritis (RA) and the use of immunosuppressive drugs, increase the risk of…Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…Abstract Number: 173 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Background/Purpose: Background: Current recommendations for latent tuberculosis infection (LTB) screening and treatment in patients eligible for anti-TNF agents are not well established in endemic regions.…Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Tuberculosis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
ACR Meeting Abstracts